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Abstract: Signal Transducer and Activator of Transcription 3 (STAT3) is activated  
in a majority of cancers, and promotes tumorigenesis and even metastasis through 
transcriptional activation of its target genes. Recently, we discovered that STAT3 
suppresses epithelial-to-mesenchymal transition (EMT) and thus metastasis in a mouse 
model of colorectal cancer (CRC), while it did not affect the overall tumor burden. 
Furthermore, we found that STAT3 in intestinal epithelial cells (IEC) suppresses EMT by 
regulating stability of an EMT inducer, SNAI-1 (Snail-1). Here, STAT3 functions as an 
adaptor rather than a transcription factor in the post-translational modification of SNAI-1. 
In this review, we discuss the unexpected and contradictory role of STAT3 in metastasis of 
CRC and its clinical implications. 
Keywords: signal transducer and activator of transcription 3 (STAT3); colorectal cancer 
(CRC); metastasis; epithelial to mesenchymal transition (EMT); Snail-1 (SNAI-1); 
glycogen synthase kinase 3β (GSK3β); Snail; adenomatous polyposis coli (APC); tight 
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1. Colorectal Cancer (CRC) 
CRC is the second most frequent cancer, after lung cancer, that leads to death in the US and  
Europe [1]. The development of sporadic human CRC is driven by the accumulation of somatic 
mutations in oncogenes (gain-of-function) and/or tumor-suppressor genes (loss-of-function), as well as 
epigenetic changes. Three etiological subtypes of genomic instability in CRC have been described, 
including chromosomal instability (CIN), microsatellite instability (MSI), and its related phenomenon 
known as the CpG island methylator phenotype (CIMP).  
CIN is the most common cause of CRC (80%–85%) and is associated with a poor prognosis [2]. 
CIN in CRC is characterized by chromosomal rearrangements (unbalanced translocation, deletion) and 
abnormality in chromosome numbers (gain or loss of whole chromosomes) [3]. Additionally, CIN is 
caused by somatic mutations in genes that regulate the mitotic spindle checkpoint, DNA replication 
checkpoints, DNA damage checkpoints, chromosome metabolism, or centrosome function [2,4]. The 
CIN phenotype is used to measure intercellular heterogeneity in chromosome number and describe 
cancers with aneuploidy, polyploidy, or loss of heterozygosity (LOH) [5]. Gain or loss of the 
chromosomal copy number contributes to development and/or progression of cancer via inactivation of 
tumor suppressor genes, activation of oncogenes, or change in gene dosage (increasing or decreasing 
expression of these genes) [6]. In fact, copy number alterations seem to be the major mechanism for 
transcriptional deregulation of cancer genes in CRC [7].  
Loss of function of mismatch-repair (MMR) genes (MLH1, MSH2, MSH6, and PMS2) is 
responsible for the epiphenomenon of MSI, which is associated with mutations in tumor-suppressor 
genes. CIMP involves epigenetic silencing of tumor suppressor genes, such as MLH1, due to aberrant 
DNA methylation (promoter hypomethylation of oncogenes or hypermethylation of tumor suppressor 
genes). This oncogenic mechanism shows overlap with MSI in CRC subgroups [8]. MSI occurs in 
~15% of CRC patients, and MSI+ CRC has a better prognosis when compared with CIN− or MSI− 
CRC. Approximately 20% of CRC patients are CIMP+. 
Whereas MSI+ CIMP+ CRC confers a better prognosis for CRC, patients with MSI− CIMP+ CRC 
have a worse prognosis [9]. Recently, De Sousa e Melo et al. [10] confirmed the existence of multiple 
CRC subtypes by gene expression profiling. They identified three categories, including colon cancer 
subtypes that correspond to the CIN+ or MSI/CIMP+ class, respectively. In addition, they identified a 
third subclass that was characterized by hallmarks of epithelial-mesenchymal transition (EMT), shared 
features with sessile serrated adenoma, and conferred a poor prognosis in CRC [10]. Sadanandam et al. 
proposed an alternative classification system based on gene expression profiling of primary CRC 
tumors [11]. These novel CRC subtypes included enterocyte, goblet-like, transit-amplifying, inflammatory, 
and stem-like tumor cells, correlating with their colon-crypt location, Wnt activity, and response to 
adjuvant or metastatic treatment [11]. In addition to their prognostic features, a higher resolution of 
CRC subtypes allows for better stratification of CRC patients in clinical trials, and may better predict 
their response to targeted therapy. Importantly, despite all these novel insights, the molecular events 
that lead to tumor invasion and metastasis are still largely unknown. 
With regard to oncogenic pathways, CIN is associated with inactivating mutations in the APC 
(adenomatous polyposis coli) gene or, to a lesser extent, gain-of-function mutations in the CTNNB1  
(β-catenin) gene. These mutations result in the formation of an early adenoma. This is followed by the 
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adenoma-to-carcinoma transition (in CIN) through sequential genetic mutations in oncogenes (e.g., 
KRAS, PIK3CA, PTEN, or EGFR/ERBB family members) and/or tumor suppressor genes (e.g., TP53, 
SMAD4, BAX) [12,13]. While germline mutations in the APC gene are responsible for familial 
adenomatous polyposis (FAP), somatic mutations in APC occur in ~90% of sporadic colorectal 
tumors. These mutations in APC lead to unrestricted activation of β-catenin, which in turn activates 
many genes responsible for tumorigenesis, such as MYC. In fact, an integrated genetic analysis by The 
Cancer Genome Atlas (TCGA) Network showed that nearly 100% of CRC tumors showed changes in 
transcriptional targets of MYC [13].  
Most of CRC-related mortality is due to metastasis, which develops in at least 50% of CRC 
patients, and the majority of metastatic tumors are not surgically resectable [14]. Thus, it is critical to 
understand the mechanisms underlying CRC metastasis. 
The most widely used animal model of CRC is the Apcmin/+ mouse strain in which multiple 
intestinal neoplasia (min) spontaneously develop, mostly in the small intestine. Adenomas in this 
model generally do not progress to adenocarcinomas. Nonetheless, this model has been an important 
tool to understand tumorigenesis and metastasis of CRC. We made a conditional deletion of STAT3 in 
IEC of these mice (Apcmin/+/Stat3IEC-KO mice) to investigate the role of STAT3 in CRC and found an 
anti-carcinogenic role for STAT3 [15], which was unexpected given a plethora of literature supporting 
the pro-oncogenic role of STAT3. Musteanu et al. also reported this anti-invasive role for STAT3 [16]. 
Together, these data suggest that STAT3 suppresses malignant transformation of adenomas in the 
Apcmin/+ mouse strain. 
2. STAT3 Signaling and Its Role in Cancers  
STAT3 plays an essential role in a variety of physiological functions, including development, 
proliferation, and immune defense [17–20]. STAT3 is phosphorylated on a tyrosine residue (Tyr-705) 
by an upstream kinase, JAK2 (Janus kinase 2). In addition to phosphorylation at Tyr-705, STAT3 is 
phosphorylated at Ser-727 and acetylated at Lys-685 [21], which is thought to be required for its full 
transcriptional activity. The phosphorylated protein forms either a homodimer or a heterodimer with 
other STAT proteins, then translocates to the nucleus and transcribes target genes. However, STAT3 
can also regulate expression of certain target genes (e.g., RANTES, IL-6, IL-8, Met, and M-Ras) in a 
phosphorylation-independent manner [22,23]. Several non-transcriptional functions of STAT3 have 
also been reported. STAT3 functions as an adaptor protein, connecting IFNAR1 (interferon α receptor 1) 
and the p85 regulatory subunit of PI3K (phosphoinositide 3-kinase) [24], and it inhibits stathmin that 
depolymerizes microtubules [25]. Activated STAT3, through interaction with phosphorylated paxillin 
and focal adhesion kinase (FAK), was shown to promote ovarian cancer cell invasiveness [26]. 
Numerous in vitro and in vivo studies indicate that STAT3 promotes tumorigenesis of a variety of 
cancers, thus it is generally recognized as an oncogene. STAT3 is activated in 70% of all solid and 
hematological tumors [27,28], and it was found activated in 72% of colorectal carcinomas but only in 
18% of colorectal adenomas [29]. Furthermore, p-STAT3 expression is associated with a poor 
prognosis in CRC, independent of MSI, CIMP, BRAF, or KRAS mutation status [30]. STAT3 is rarely 
mutated in cancer cells but rather activated by upstream signals, such as receptor tyrosine kinses 
(RTKs), mutated JAKs, or oncogenic cellular tyrosine kinases (CTKs), such as Src. Recently, somatic 
mutations in the SH2 dimerization and activation domain of STAT3 were discovered in 40% of 
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patients with large granular lymphocytic leukemia, and these mutations were associated with enhanced 
phosphorylation of STAT3 and its localization in the nucleus [31].  
3. STAT3 in Intestinal Epithelial Cells (IEC) Promotes Cell Survival and Epithelial Barrier Function 
Membranes of IEC, like any epithelium, are polarized with tight junctions as the boundary. The 
apical membrane, facing the lumen, expresses distinctive proteins (e.g., digestive enzymes, nutrient 
transporters, etc.) in IEC. Conversely, proteins in the basolateral membrane resemble those in other 
unpolarized cell types [32]. This is achieved by complex and coordinated protein sorting and targeting 
machinery [33]. We have shown that TLR9 is expressed in both the apical and basolateral membranes, 
but only apical TLR9 generates a response that suppresses the inflammatory responses of basolateral 
TLRs, including TLR3, TLR5, and TLR9 [32]. This was surprising for three main reasons. First, since 
TLR9 is expressed in endosomes of immune cells, our data indicate that localization of TLR9 is not 
determined by its primary sequence. Second, it indicates that different downstream effectors of the 
same receptor (TLR9) are utilized depending on the location of the receptor. Whether this is unique to 
TLR9 remains to be seen. Third, when IEC lose polarity (by culturing on a plastic surface), TLR9 
signaling mainly resembles that of the basolateral TLR9 (inflammatory). We suspect that intracellular 
signaling cascades in IEC could be altered under pathological conditions where polarity is disrupted 
(e.g., inflammation or cancer). Recently, we found such an example: interferon α (IFNα) activates 
STAT3 preferentially in polarized IEC, while it activates both STAT1 and STAT3 to the same extent 
in unpolarized IEC (Figure 1A). STAT1 is rapidly degraded by the proteasome upon IFNα stimulation 
in polarized IEC, which can be rescued by blockade of the proteasome (Figure 1B). Regulation of 
STAT1 signaling by polarization in IEC resulted in a distinctive pattern of gene expression upon IFNα 
stimulation (Figure 1C): more inflammatory genes, such as IRF-1 and STAT1, were induced in 
unpolarized IEC, whereas anti-apoptotic genes, such as Bcl-2, were induced in polarized IEC. SLIM, a 
ubiquitin ligase of STAT1 [34], was also induced by IFNα in polarized IEC, which is consistent with 
the result that STAT1 is degraded by the proteasome under this condition. Thus, from these results and 
other evidence in the literature, it was expected that STAT3 in IEC should promote tumorigenesis by 
preventing apoptosis.  
However, we also found that STAT3 promotes polarization of IEC, measured by trans-epithelial 
electrical resistance (TER), and reduces trans-epithelial permeability, a measure of barrier function 
(Figure 2). Since carcinomas typically lose polarity before metastasis, our data also suggest that 
STAT3 might inhibit EMT and thus metastasis of CRC. 
4. STAT3 Does Not Affect Intestinal Tumor Initiation  
Contrary to the expectation that STAT3 would be a major driver of tumorigenesis but consistent 
with the data by Musteanu et al. [16], we found that STAT3 in IEC plays only a minor role in tumor 
initiation in the Apcmin/+ model. However, both groups observed a dramatic increase in tumor invasion 
of Apcmin/+ tumors in the intestines upon deletion of Stat3 in IEC in vivo. It must be noted that some of 
our observations in the Apcmin/+/Stat3IEC-KO strain differ from those reported by Musteanu et al [16]. 
Whereas they observed a slight reduction in tumor multiplicity at a late stage [15], we found that the 
number of adenomas in the small and large intestine did not significantly change in Apcmin/+/Stat3IEC-KO 
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mice [15]. Furthermore, they observed an increased rate of IEC proliferation and nuclear translocation 
of β-catenin in tumors of Apcmin/+/Stat3IEC-KO mice [16], whereas we found no differences in these 
parameters [15]. Interestingly, Musteanu et al. [16] observed increased p-STAT3 levels in Apcmin/+ 
adenomas [16], and we found that total STAT3 expression in adenomas was substantially higher than 
that in normal IEC (unpublished data). These data both suggest that STAT3 is highly activated in 
tumor cells, since STAT3 activates its own transcription [35]. In the Apcmin/+ model, β-catenin is the 
driver of tumorigenesis and STAT3 has been directly implicated in the activation of β-catenin. For 
example, the expression of a dominant negative (DN)-STAT3 or pharmacological inhibition of 
JAK/STAT3 signaling induced translocation of β-catenin from the nucleus to the cytoplasm. This 
resulted in reduced transcriptional activity of β-catenin and inhibition of cell proliferation [36]. In 
contrast, Musteanu et al. proposed that STAT3IEC-KO resulted in down-regulation of the cell adhesion 
protein, CEACAM1, with a concomitant increase in nuclear β-catenin [16]. However, we did not 
observe this change in localization of β-catenin and therefore propose an alternative model in which 
STAT3 negatively regulates EMT.  
Figure 1. STAT3 is preferentially activated by IFNα, while STAT1 is degraded by the 
proteasome in polarized IEC. (A) Polarized or unpolarized HCA-7 cells were stimulated 
with IFNα (10 ng/mL) for the indicated time period and the indicated proteins were 
measured by immunoblotting; (B) Polarized HCA-7 cells were stimulated with IFNα  
(10 ng/mL) for the indicated time period in the absence or presence of MG132 (10 µM) 
and the indicated proteins were measured by immunoblotting. To detect ubiquitination of 
STAT1, STAT1 was immunoprecipitated and blotted with anti-ubiquitin antibody;  
(C) Polarity-dependent gene activation by IFNα in IECs. Polarized (P) or unpolarized (UP) 
HCA-7 cells were stimulated with IFNα (10 ng/mL) for 1 hr and the induction of indicated 
genes by IFNα was measured by qPCR. The data represents one of two independent 
experiments with similar results. 
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Figure 2. STAT3 promotes polarization and barrier function of IEC in vitro and in vivo. 
(A) STAT3 in HCA-7 cells was silenced by RNAi and the indicated proteins were 
measured by immunoblotting; (B) Cells transfected with the indicated siRNA were plated 
on a Transwell plate and transepithelial electrical resistance (TER) was measured at the 
indicated time. (n = 6) (* represents p value < 0.05, ANOVA); (C) The barrier function of 
HCA-7 cells was assessed by using FITC-sulfonic acid (FS). FS was measured five days 
after transfection (n = 6); (D) The deletion of STAT3IEC in mice was confirmed by 
immunohistochemistry (IHC) as described [37]. STAT3 staining (brown) in the KO mice is 
confined to mononuclear cells in the LP (Lamina Propria) but is absent in IEC; (E) 
Intestinal permeability of KO mice is significantly higher than that of WT mice (p = 0.001). 
Mice were gavaged with FITC-dextran (FD, MW 4000, 6 mg/mouse) and the level of FD 
in serum was measured 90 min post administration. 
 
It is important to note that STAT3 is essential for tumorigenesis in the colitis-associated cancer 
(CAC) model in mice [38,39]. This model employs a carcinogen (azoxymethane) to induce 
mutagenesis, which is followed by repeated administration of DSS (dextran sulfate sodium) to induce 
chronic colitis [40]. Metastasis in this model is still dependent on mutations in the β-catenin gene [41]. 
Although dysfunctional APC can affect molecules other than β-catenin, β-catenin is essential for 
intestinal tumorigenesis. How does STAT3 play such a contradictory role in sporadic versus  
colitis-induced CRC? We found that STAT3-deficient IEC are highly sensitive to DSS-induced death 
(unpublished data in Stat3IEC-KO mice), as reported by Grivennikov et al. [38]. It is possible that 
potential STAT3-deficient cancer cells in this model may not have survived the repeated DSS 
treatments in the CAC model. The Apcmin/+ model is not driven by the carcinogenic effects of 
inflammation or any other chemical interventions. Thus, the effect of epithelial STAT3 signaling on 
tumor initiation is likely very different in sporadic CRC versus CAC.  
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5. STAT3 Suppresses Adenoma to Adenocarcinoma Transition 
While tumorigenesis was only minimally affected by deletion of STAT3, tumors in Apcmin/+/Stat3IEC-KO 
mice invaded deeply into the mucosal stroma, submucosa, and muscle, indicating that STAT3 
suppresses metastasis [15,16]. Epithelial-to-mesenchymal transition (EMT) is an integral process of 
metastasis and generally considered a prerequisite [42–45]. Epithelial cells are tightly interlocked with 
each other by junctional complexes, including tight junctions (TJ) and adherens junctions (Figure 1). 
Loss of junctional proteins such as E-cadherin, an adherens junction protein, is a hallmark of EMT and 
metastasis in many cancers [46–48]. Cancer cells that acquired a mesenchymal phenotype express 
prototypical mesenchymal proteins, such as vimentin and fibronectin, as well as various 
metalloproteinases. STAT3 is reportedly involved in IL-6-induced EMT in head and neck tumor 
metastasis [49], and promotes metastasis of melanoma to the brain by induction of the extracellular 
matrix-degrading metalloproteinases, including MMP-2 and MMP-9 [50].  
In contrast, we found that STAT3 plays an opposite role in the Apcmin/+ model. Intestinal adenomas 
in Apcmin/+ mice did not show down-regulation of E-cadherin, while there was a remarkable  
down-regulation of the TJ protein, CLDN-3 (claudin-3) when compared to normal IEC [51]. 
Furthermore, expression of CLDN-3 and CLDN-5 in tumor cells was markedly decreased in tumor 
cells of Apcmin/+/Stat3IEC-KO mice compared with those in Apcmin/+ mice; there was no difference in  
E-cadherin or occludin levels. More importantly, all tumors in Apcmin/+/Stat3IEC-KO mice expressed high 
levels of vimentin and, in some tumors, fibronectin, whereas those in Apcmin/+ mice rarely expressed 
either [15]. Results showing the loss of TJ proteins [51] and slight elevation of vimentin [52] suggest 
that a low grade of EMT is initiated in Apcmin/+ mice and indicate that STAT3 deletion can accelerate 
this process. As discussed above, Musteanu et al. proposed that STAT3 impairs invasion of IEC 
tumors via the cell adhesion molecule, CEACAM1 [16]. Therefore, STAT3 appears to be intimately 
involved in cell adhesion of IEC and other epithelial cell types. 
Expression of activated STAT3 in colon cancer cells (HT-29 or CoGa-1) induced 
metalloproteinases MMP1, MMP3, MMP7, and MMP9, which were demonstrated to aid invasiveness 
of these cells [53]. Our data showed that, while MMP9 and MMP15 (MT2-MMP) expression in tumor 
cells was negligible in both Apcmin/+ and Apcmin/+/Stat3IEC-KO mice, MMP7 expression in tumor cells 
was significantly lower in Apcmin/+/Stat3IEC-KO mice. These data indicate that MMP7, MMP9, and 
MMP15 are not likely to contribute to tumor invasion in these mice. However, MMP14 (MT1-MMP) 
expression in tumor cells was highly elevated in Apcmin/+/Stat3IEC-KO mice but undetectable in Apcmin/+ 
mice. Since MMP14 is particularly efficient in hydrolyzing basement membranes [54,55], it may be 
involved in tumor invasion in Apcmin/+/Stat3IEC-KO mice. Furthermore, overexpression of the MT1-MMP 
gene is reported as a useful predictor of outcomes in patients with CRC [56]. Several MT1-MMP 
inhibitors are under development for cancer therapy [57].  
6. STAT3 Inhibits Tumor Invasion via Regulation of an EMT Inducer SNAI-1 
EMT is induced by a group of transcription repressors, including SNAI-1, Slug, Zeb-1, Zeb-2, 
Twist, E47, and KLF. These factors directly or indirectly repress transcription of E-cadherin and other 
junction proteins, including claudins and desmosomes, thereby facilitating EMT [42–45]. Among the 
tested EMT inducers, only SNAI-1 was significantly elevated in tumors of Apcmin/+/Stat3IEC-KO  
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mice [15]. Silencing STAT3 in a few human CRC cell lines also induced expression of SNAI-1 but  
not other EMT inducers, while overexpression of STAT3-WT suppressed SNAI-1 expression. STAT3 
knockdown significantly increased the invasiveness of a CRC cell line, HCT116, which was 
completely dependent on SNAI-1 [15]. Our data are directly contradictory to a previous study in which 
STAT3 reportedly increased the invasiveness of HT-29 or CoGa-1 [53]. HCT116 cells are APCWT, 
whereas both HT-29 and CoGa-1 cell lines carry APC mutations. This suggests that the suppression of 
EMT by STAT3 is not dependent on constitutive activation of Wnt signaling. Furthermore,  
Xiong et al. reported that STAT3 mediates down-regulation of E-cadherin through Zeb-1, thereby 
promoting EMT and the invasive properties of CRC [58], which is also contradictory to our findings. 
Their observations were mainly done in human CRC lines SW1116 and LoVo [58], which were 
derived from a primary tumor and metastasized CRC, respectively, and carry APC mutations. Finally, 
another report suggested that STAT3 inhibition negatively regulated the migratory and invasive 
properties of HCT116 cells [59]. Differential in vitro conditions may cause STAT3 to have opposite 
effects on EMT, even within the same cell line, an issue that remains to be clarified. The tumor 
microenvironment, which is lost in CRC cell line cultures, dictates the metastatic capacity of 
disseminated CRC cells in vivo. In this regard, the GP130/STAT3 signaling axis has been shown to 
contribute to CRC metastasis [60]. Thus, STAT3 displays both pro- and anti-metastatic effects in 
CRC, the outcome of which may be determined by the tumor microenvironment.  
7. STAT3 Coordinates SNAI-1 Stability as a Molecular Adaptor 
Unexpectedly, STAT3 deletion or knockdown in IEC did not significantly affect the transcription of 
SNAI [15], indicating that STAT3 regulates SNAI-1 at a post-transcriptional level. SNAI in a CRC 
cell line was constitutively ubiquitinated and degraded by proteasomes. STAT3 knockdown increased 
the level of SNAI-1 but diminished the level of SNAI ubiquitination [15], indicating that STAT3 
facilitates ubiquitination of SNAI-1. Phosphorylation of SNAI-1 by GSK3β at two different sites 
regulates the fate of SNAI-1 during EMT: phosphorylation of the first motif induces ubiquitination of 
SNAI-1, whereas phosphorylation of the second motif controls its subcellular localization [61]. As 
expected, we found that pharmacological inhibition or knockdown of GSK3β elevated the SNAI-1 
level in a CRC cell line [15]. STAT3 and GSK3β co-immunoprecipitated, but expression of STAT3 
protein was not affected by GSK3β or vise versa. However, whether STAT3 has to be phosphorylated 
to interact with GSK3β is still to be determined. STAT3 knockdown elevated phosphorylation on Ser9 
of GSK3β, which inhibits its kinase activity [62]. GSK3β is also involved in activation of β-catenin, 
but GSK3α can compensate for the absence of GSK3β [63]. This may explain why there were no 
changes in β-catenin levels. Ectopic expression of a constitutively active GSK3β mutant in a CRC cell 
line not only reversed the SNAI-1 induction but also abrogated the invasiveness caused by STAT3  
depletion [15]. In summary, these results demonstrate that STAT3 acts as a molecular adaptor to 
regulate GSK3β activity, and thus SNAI-1 expression and EMT (Figure 3). It is not clear how STAT3 
regulates GSK3β activity, but it may be by acting as a bridge between GSK3β and SNAI-1 to facilitate 
phosphorylation. In addition, whether the interaction among these three proteins occurs in the 
cytoplasm or nucleus needs to be investigated.   
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Figure 3. STAT3 suppresses EMT by promoting GSK3β-mediated phosphorylation and 
proteasomal degradation of SNAI-1 in IEC. STAT3 inhibits phosphorylation of GSK3β 
(active), which phosphorylates SNAI-1, leading to ubiquitination and degradation. 
Consequently, epithelial cell markers, such as claudins, are upregulated and mesenchymal 
markers, such as vimentin and fibronectin, are down-regulated. When STAT3 is deleted 
from IEC, unknown environmental cue(s) induce phosphorylation of GSK3β (inactive), 
most likely via the Akt pathway, leading to accumulation of SNAI and EMT. 
 
8. Clinical Implications 
Because of the vast amount of literature supporting the oncogenic role of STAT3, several 
approaches to inhibit STAT3 activity have been developed for potential clinical trials. These include 
inhibitors of upstream molecules, such as IL-6 [64] or JAK2 [65,66], and direct inhibition of STAT3 
with a STAT3 decoy oligonucleotide [67] or siRNA [68]. While the outcome of these clinical trials 
should tell us whether STAT3 inhibition is truly efficacious, caution is warranted for CRC trials with 
direct STAT3 inhibition.  
If our model is correct, we should expect adverse effects of direct inhibition of STAT3 in CRC, 
while targeting upstream molecules such as IL-6 or JAK2 is more complicated, as many targets other 
than STAT3 could be influenced by these approaches. Another possibility is that the outcome of direct 
inhibition of STAT3 in CRC is dependent on the underlying genetic or epigenetic background. This 
becomes increasingly complex when considering the role of STAT3 in non-tumor cells in metastasis 
(i.e., the tumor microenvironment), as cancer drugs rarely discriminate normal cells from tumor cells. 
Only further investigations and the outcomes of clinical trials may provide more clarity.    
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9. Conclusions 
Our data and the data from Mesteanu et al. suggest that STAT3 can act as an anti-invasive factor 
under certain conditions [15,16]. The potential anti-EMT and anti-invasive role of STAT3 warrants 
rigorous follow-up studies, considering the depth of literature supporting its role as a strong promoter 
of tumorigenesis and eventual metastasis. Ongoing and future clinical trials on CRC with an agent 
directly inhibiting STAT3 activity should provide more insight into this paradoxical function of STAT3.  
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